News

Silexion Therapeutics Sees Positive Stock Movement, Strong Trial Results

Silexion Therapeutics Sees Positive Stock Movement, Strong Trial Results

Positive Movement in Silexion Therapeutics' Stock

Silexion Therapeutics Corp. (NASDAQ: SLXN) has experienced a significant rise in its stock price, climbing over 21.72% during pre-market trading. This surge follows the release of promising results from a Phase 2 clinical trial centered on their innovative product, LODER.

Key Findings from the Phase 2 Trial

The analysis revealed an impressive 56% objective response rate (ORR) for patients who received treatment with LODER. Notably, among those whose previously inoperable tumors transitioned to being suitable for resection, the response rate jumped to 67%.

Improved Survival Rates

Silexion previously indicated that patients treated with LODER alongside standard chemotherapy saw a meaningful boost in overall survival. Specifically, this group experienced a 9.3-month increase in survival time compared to those who did not receive LODER treatment.

Enhancing Surgical Options

The latest data underscores LODER's potential to improve tumor resectability, offering additional surgical choices for patients facing pancreatic cancer. This presents a promising alternative for individuals who were previously deemed inoperable.

Advancements in Product Development

Alongside LODER, Silexion Therapeutics is making strides with their next-generation product, SIL-204. This new therapy is specifically crafted to address a wider range of KRAS mutations.

Strategic Partnerships and Growth

In a major strategic move, Silexion Therapeutics merged with Moringa Acquisition Corp, a publicly traded special purpose acquisition company, along with Biomotion Sciences. This merger enabled the newly formed organization to rebrand itself as Silexion Therapeutics.

Current Stock Price Trends

As of the latest updates, SLXN stock was trading at $0.91, reflecting an 18.3% gain during the pre-market session. The ongoing developments paired with encouraging trial outcomes indicate strong potential for future growth.

Frequently Asked Questions

What is the recent stock performance for Silexion Therapeutics?

Silexion Therapeutics' stock has risen over 21.72% in pre-market trading, fueled by positive trial results.

What were the key findings of the Phase 2 trial?

The Phase 2 trial demonstrated a 56% overall response rate, increasing to 67% for patients whose tumors became resectable.

How does LODER impact survival rates?

Patients treated with LODER in combination with chemotherapy experienced an increase in overall survival of 9.3 months.

What advancements is Silexion making in drug development?

Silexion is actively developing SIL-204, which targets a broader array of KRAS mutations for improved treatment options.

What is the current stock price of SLXN?

As of the latest report, SLXN is priced at $0.91 in the pre-market session, reflecting strong interest from investors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 104

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Cold Stone’s Holiday Menu Is a Franchisee Traffic Test

Updated Category News Views 56

Peppermint, caramel, and red velvet arrive right when dessert budgets loosen up. Cold Stone Creamery has rolled out a holiday menu running through January 5, 2027, and this is the sort of modest, practical promotion that matters more to a franchise system than the glittery language around it. Nobody should confuse two seasonal ice cream flavors with a corporate...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 104

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
California's AI Oversight Roadmap Raises the Bar Early

Updated Category News Views 41

California has put a real set of teeth on the table, at least on paper. Governor Gavin Newsom's November 18 roadmap for implementing the state's new AI laws embraces an independent verification organization, or IVO, framework that Fathom has been pushing: outside evaluators, licensed by the state, examining whether frontier AI systems create catastrophic risks. For anyone...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 114

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 58

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 66

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 0

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 139

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 229

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US to Showcase Innovations at Capital Markets Day

Updated Category News Views 104

T-Mobile US, Inc. Unveils Plans at Deutsche Telekom Capital Markets Day BELLEVUE, Wash. — T-Mobile US, Inc. (NASDAQ: TMUS) is gearing up to present at the highly anticipated Deutsche Telekom Capital Markets Day, a pivotal event that showcases the company's strategic vision and operational milestones. The presentation will feature insights from Mike Sievert, T-Mobile’s...

Continue Reading
Earnings Insights for Edwards Lifesciences: What to Expect

Updated Category News Views 84

Understanding Edwards Lifesciences's Expected Earnings Release Edwards Lifesciences (NYSE: EW) is gearing up to announce its quarterly earnings, creating a buzz among investors eager for insights on the company's performance. With analysts forecasting an earnings per share (EPS) of $0.65, stakeholders are looking forward to how these results may impact the stock price and...

Continue Reading
Understanding ezPaycheck: A Smart Solution for Restaurant Payroll

Updated Category News Views 139

Introducing ezPaycheck: Tailored Payroll Solution for Restaurants ezPaycheck is designed for restaurant owners who prioritize precision and efficiency in managing payroll. This cutting-edge software allows users to streamline their payroll processes, offering a risk-free trial for up to 30 days to evaluate compatibility with existing systems. Why Choose ezPaycheck for...

Continue Reading
Revolutionizing Pet Compliance with AI: PetScreening Unveils Tool

Updated Category News Views 638

PetScreening Introduces Innovative AI Compliance Tool The solution will help operators capture pet-related revenue that otherwise would have been lost. PetComply.ai Launch Today, PetScreening, a leader in pet policy compliance software, has launched PetComply.ai, an exclusive feature designed to assist property managers in identifying undisclosed pets by renters. This...

Continue Reading
STRATA Skin Sciences Announces Participation in Investor Conference

Updated Category News Views 99

STRATA Skin Sciences Joins the Benchmark Company Investor Conference STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a pioneering medical technology company focused on innovative solutions for dermatologic conditions, has announced participation in the upcoming Benchmark Company 13th Annual Discovery Investor Conference. This event will take place at the New York Athletic...

Continue Reading